X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (118) 118
index medicus (75) 75
antitubercular agents - therapeutic use (73) 73
capreomycin - therapeutic use (73) 73
capreomycin (70) 70
tuberculosis (69) 69
mycobacterium tuberculosis - drug effects (58) 58
female (57) 57
male (52) 52
pharmacology & pharmacy (45) 45
adult (44) 44
tuberculosis, multidrug-resistant - drug therapy (42) 42
tuberculosis, pulmonary - drug therapy (41) 41
microbiology (39) 39
infectious diseases (37) 37
ethambutol - therapeutic use (35) 35
middle aged (35) 35
microbial sensitivity tests (34) 34
mycobacterium-tuberculosis (34) 34
drug resistance (32) 32
rifampin - therapeutic use (32) 32
kanamycin (30) 30
tuberculosis - drug therapy (30) 30
isoniazid - therapeutic use (29) 29
amikacin (27) 27
mycobacterium tuberculosis - isolation & purification (25) 25
capreomycin - administration & dosage (23) 23
capreomycin - pharmacology (23) 23
mutation (23) 23
antitubercular agents - pharmacology (22) 22
drug resistance in microorganisms (22) 22
drug resistance, microbial (22) 22
drug therapy, combination (22) 22
kanamycin - therapeutic use (22) 22
mycobacterium tuberculosis (22) 22
animals (21) 21
antitubercular agents (21) 21
drugs (21) 21
extensively drug-resistant tuberculosis - drug therapy (21) 21
mycobacterium tuberculosis - genetics (19) 19
tuberculosis, multidrug-resistant - microbiology (19) 19
drug therapy (18) 18
isoniazid (18) 18
rifampin (18) 18
administration, inhalation (15) 15
antitubercular agents - administration & dosage (15) 15
antitubercular agents - adverse effects (15) 15
capreomycin - adverse effects (15) 15
drug resistance, multiple, bacterial - genetics (15) 15
treatment outcome (15) 15
aged (14) 14
amikacin - therapeutic use (14) 14
analysis (14) 14
antibiotics (14) 14
mutations (14) 14
pulmonary tuberculosis (14) 14
pyrazinamide - therapeutic use (14) 14
respiratory system (14) 14
retrospective studies (14) 14
streptomycin - therapeutic use (14) 14
strains (13) 13
tuberculosis, pulmonary - microbiology (13) 13
cross-resistance (12) 12
ethionamide - therapeutic use (12) 12
multidrug-resistant (12) 12
particle size (12) 12
rifampicin (12) 12
sputum - microbiology (12) 12
amikacin - pharmacology (11) 11
aminosalicylic acids - therapeutic use (11) 11
ethambutol (11) 11
kanamycin - pharmacology (11) 11
ofloxacin (11) 11
research (11) 11
research article (11) 11
time factors (11) 11
tuberculosis, multidrug-resistant - diagnosis (11) 11
xdr-tb (11) 11
young adult (11) 11
adolescent (10) 10
capreomycin - chemistry (10) 10
ethionamide (10) 10
extensively drug-resistant tuberculosis - epidemiology (10) 10
fluoroquinolones - therapeutic use (10) 10
genotype (10) 10
laboratories (10) 10
medicine (10) 10
public health (10) 10
pyrazinamide (10) 10
resistance (10) 10
rifampin - pharmacology (10) 10
streptomycin (10) 10
aminoglycosides (9) 9
bacterial proteins - genetics (9) 9
care and treatment (9) 9
clinical trials as topic (9) 9
drug delivery systems (9) 9
fluoroquinolones (9) 9
inhalation (9) 9
multidisciplinary sciences (9) 9
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (144) 144
German (8) 8
French (3) 3
Japanese (3) 3
Polish (3) 3
Chinese (2) 2
Russian (2) 2
Czech (1) 1
Korean (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Ahmad, Nafees and Ahuja, Shama D and Akkerman, Onno W and Alffenaar, Jan-Willem C and Anderson, Laura F and Baghaei, Parvaneh and Bang, Didi and Barry, Pennan M and Bastos, Mayara L and Behera, Digamber and Benedetti, Andrea and Bisson, Gregory P and Boeree, Martin J and Bonnet, Maryline and Brode, Sarah K and Brust, James C M and Cai, Ying and Caumes, Eric and Cegielski, J Peter and Centis, Rosella and Chan, Pei-Chun and Chan, Edward D and Chang, Kwok-Chiu and Charles, Macarthur and Cirule, Andra and Dalcolmo, Margareth Pretti and D'Ambrosio, Lia and de Vries, Gerard and Dheda, Keertan and Esmail, Aliasgar and Flood, Jennifer and Fox, Gregory J and Fréchet-Jachym, Mathilde and Fregona, Geisa and Gayoso, Regina and Gegia, Medea and Gler, Maria Tarcela and Gu, Sue and Guglielmetti, Lorenzo and Holtz, Timothy H and Hughes, Jennifer and Isaakidis, Petros and Jarlsberg, Leah and Kempker, Russell R and Keshavjee, Salmaan and Khan, Faiz Ahmad and Kipiani, Maia and Koenig, Serena P and Koh, Won-Jung and Kritski, Afranio and Kuksa, Liga and Kvasnovsky, Charlotte L and Kwak, Nakwon and Lan, Zhiyi and Lange, Christoph and Laniado-Laborín, Rafael and Lee, Myungsun and Leimane, Vaira and Leung, Chi-Chiu and Leung, Eric Chung-Ching and Li, Pei Zhi and Lowenthal, Phil and Maciel, Ethel L and Marks, Suzanne M and Mase, Sundari and Mbuagbaw, Lawrence and Migliori, Giovanni B and Milanov, Vladimir and Miller, Ann C and Mitnick, Carole D and Modongo, Chawangwa and Mohr, Erika and Monedero, Ignacio and Nahid, Payam and Ndjeka, Norbert and O'Donnell, Max R and Padayatchi, Nesri and Palmero, Domingo and Pape, Jean William and Podewils, Laura J and Reynolds, Ian and Riekstina, Vija and Robert, Jérôme and Rodriguez, Maria and Seaworth, Barbara and Seung, Kwonjune J and Schnippel, Kathryn and Shim, Tae Sun and Singla, Rupak and Smith, Sarah E and Sotgiu, Giovanni and Sukhbaatar, Ganzaya and Tabarsi, Payam and Tiberi, Simon and Trajman, Anete and Trieu, Lisa and Udwadia, Zarir F and van der Werf, Tjip S and Veziris, Nicolas and Viiklepp, Piret and ... and Collaborative Grp Meta-Analysis In and Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017
The Lancet, ISSN 0140-6736, 09/2018, Volume 392, Issue 10150, pp. 821 - 834
Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of... 
DRUG | SURGERY | SOUTH-AFRICA | BEDAQUILINE | MEDICINE, GENERAL & INTERNAL | HIGH-RATES | MANAGEMENT | SAFETY | XDR-TB | REGIMENS | PROGRAM | Clofazimine - therapeutic use | Recurrence | Tuberculosis, Multidrug-Resistant - mortality | Linezolid - therapeutic use | Humans | Fluoroquinolones - therapeutic use | Tuberculosis, Pulmonary - drug therapy | Kanamycin - therapeutic use | Moxifloxacin | Capreomycin - therapeutic use | Amikacin - therapeutic use | Carbapenems - therapeutic use | Tuberculosis, Pulmonary - mortality | Diarylquinolines - therapeutic use | Treatment Failure | Antitubercular Agents - administration & dosage | Levofloxacin - therapeutic use | Drug Therapy, Combination | Antitubercular Agents - therapeutic use | Tuberculosis, Multidrug-Resistant - drug therapy | Drug resistance in microorganisms | Care and treatment | Tuberculosis | Patient outcomes | Analysis | Drugs | Fluoroquinolones | Linezolid | Levofloxacin | Amikacin | Medical services | Clinical trials | Systematic review | Drug resistance | Success | Clinical outcomes | Literature reviews | Heterogeneity | Kanamycin | Data analysis | Clofazimine | Adjustment | Mortality | Data processing | Thorax | Regression analysis | Disease control | Patients | Capreomycin | Meta-analysis | Studies | Multidrug resistant organisms | Infectious diseases | Adults | Respiration | Carbapenems
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2013, Volume 8, Issue 2, p. e55299
Background: India with a major burden of multidrug-resistant tuberculosis (MDR-TB) does not have national level data on this hazardous disease. Since 2006,... 
MYCOBACTERIUM-TUBERCULOSIS | SYSTEM | SOUTH-AFRICA | MULTIDRUG-RESISTANT | MULTIDISCIPLINARY SCIENCES | 2ND-LINE DRUGS | XDR-TB | PREVALENCE | INDIA | Sputum - microbiology | Tuberculosis, Pulmonary - microbiology | Isoniazid - pharmacology | Prevalence | Humans | Ofloxacin - therapeutic use | Male | Tuberculosis, Pulmonary - drug therapy | Capreomycin - pharmacology | Incidence | Capreomycin - therapeutic use | Ofloxacin - pharmacology | Ethionamide - pharmacology | Adult | Extensively Drug-Resistant Tuberculosis - microbiology | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | Antitubercular Agents - therapeutic use | Extensively Drug-Resistant Tuberculosis - drug therapy | Ethionamide - therapeutic use | Risk Factors | Antitubercular Agents - pharmacology | India - epidemiology | Amikacin - pharmacology | Mycobacterium tuberculosis - isolation & purification | Extensively Drug-Resistant Tuberculosis - epidemiology | Amikacin - therapeutic use | Tuberculosis, Pulmonary - epidemiology | Rifampin - pharmacology | Drug resistance in microorganisms | Tuberculosis | Research | Demographic aspects | Drug therapy | Drugs | Amikacin | Sample size | Laboratories | Ethionamide | Drug resistance | Socioeconomics | Risk factors | Demographics | Genetics | Isoniazid | Public health | Socio-economic aspects | Cultures | Risk analysis | Ofloxacin | Medical screening | Resistance factors | Patients | Capreomycin | Signaling | Infectious diseases | Disease transmission | Respiratory diseases | Liquid culture | Sputum | Mutation | Rifampin
Journal Article
Tuberculosis and Respiratory Diseases, ISSN 1738-3536, 04/2015, Volume 78, Issue 2, pp. 78 - 84
Reports of therapeutic drug monitoring (TDM) for second-line medications to treat multidrug-resistant tuberculosis (MDR-TB) remain limited. A retrospective... 
Linezolid | Moxifloxacin | Pharmacokinetics | Cycloserine | Capreomycin | Original
Journal Article
Journal Article
International Journal of Tuberculosis and Lung Disease, ISSN 1027-3719, 02/2014, Volume 18, Issue 2, pp. 227 - 232
Journal Article